Other languages Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Market Closed - Nyse Other stock markets 16:00:02 2024-06-21 EDT			5-day change	1st Jan Change
12.6 ^USD	-0.08%		-3.82%	-11.70%

06-21	Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	MT
06-21	Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	DJ

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	06-21
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	06-21
Les sorcières épouvantent l'IA	06-21
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	06-21
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	06-21
Borsa di Italia: Le streghe terrorizzano l'AI	06-21
Bolsa de Madrid: Las brujas aterrorizan a la IA	06-21
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	06-21
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	06-20
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	06-20
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	06-19
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	06-19
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	06-19
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	06-18
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	06-18
Sector Update: Health Care Stocks Decline Premarket Monday	06-17
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	06-17
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	06-17
Takeda's seizure drug fails to meet main goal in late-stage studies	06-17
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	06-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Takeda Pharmaceutical Company Limited Nyse

Equities

TAK

US8740602052

Other languages

Filters